Haloperidol, a D2 dopamine receptor antagonist, is a potential pharmacological option for the prevention and treatment of ICU-related delirium due to its ability to disinhibit acetylcholine and reduce the use of psychotropic sedatives/analgesics (40, 41). The gene discussed is DRD2; the disease is delirium.